Evolution Research Group | Endeavor Clinical Trials

Research site

(Unclaimed)

Location

Physicians Plaza II 8042 Wurzbach #420, San Antonio, Texas, United States of America

Site insights

Top conditions

Top treatments

HTX-011

Acetaminophen

Ibuprofen

VX-548

Bupivacaine HCl

LY3841136

Propofol

Bupivacaine Hydrochloride

HSK3486

Tirzepatide

Parent organization

This site is a part of Evolution Research Group

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

20 of 92 total trials

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling

Overweight

Obesity

Drug: LY3305677

Drug: LY3549492

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.

This is a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate HTX-011 compared with bupivacaine HCl in subjects undergoing...

Active, not recruiting

Analgesia

Drug: HTX-011

Drug: Acetaminophen

A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement

This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14...

Active, not recruiting

Post Operative Pain

Drug: 0.25 % Bupivacaine HCl

Drug: Methocarbamol

Locations recently updated

A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy

The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of VX-993 in treating acute pain after a bunionectom...

Enrolling

Acute Pain

Drug: VX-993

Drug: Placebo (matched to HB/APAP)

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safet...

Active, not recruiting

Overweight and Obesity

Obesity

Drug: Placebo

Drug: LY3841136

A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes

The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body.Participation in Part A of th...

Not yet enrolling

Overweight

Healthy

Drug: LY4086940

Drug: Placebo

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight

The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overwe...

Active, not recruiting

Overweight

Obesity

Drug: Orforglipron

Drug: Placebo

A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes (ZONE)

The goal of this clinical trial is to learn about the effect of the study drug (ZT-01) on low blood sugar (hypoglycemia) in adults with type 1 diabet...

Enrolling

Type 1 Diabetes Mellitus with Hypoglycemia

Drug: Placebo

Drug: ZT-01, 22 mg

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Elevated Lp(a)

Drug: Lepodisiran Sodium

Drug: Placebo

A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: LY3549492

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136...

Enrolling

Overweight

Obesity

Drug: Placebo

Drug: LY3841136

Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The st...

Not yet enrolling

Obesity and Overweight

Drug: GZR18

Drug: Tirzepatide

Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus

Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.

Active, not recruiting

Type 1 Diabetes Mellitus

Drug: BMF-219

Study Assessing Pain Relief After Replacement of the Knee (SPARK 2)

The goal of the ATX101-TKA-004 clinical trial aims to evaluate the efficacy and safety of ATX101 1,500 mg in participants undergoing primary unilater...

Enrolling

Total Knee Arthroplasty (Postoperative Pain)

Drug: ATX101

Drug: bupivacaine hydrochloride

Study of DISC-0974 to Assess the Safety, Tolerability, PK and PD of DISC-0974 in Participants with CKD and Anemia

This Phase 1b study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult particip...

Enrolling

Anemia of Chronic Kidney Disease

Chronic Kidney Diseases

Drug: DISC-0974

Drug: Placebo

Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease (VICTORION-2P)

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Placebo

Drug: Inclisiran sodium 300 mg

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatoh...

Enrolling

NASH

Drug: K-877-ER

Drug: Placebo

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling

Atherosclerotic Cardiovascular Disease (ASCVD)

Chronic Kidney Disease (CKD)

Drug: Retatrutide

Drug: Placebo

Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients (EURELIA1)

The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety o...

Enrolling

Hyperuricemia

Gout Flare

Drug: Placebo

Drug: Tigulixostat

Tramadol Versus Placebo and Morphine in the Management of Post-Operative Pain Abdominoplasty

This study is evaluating the analgesic efficacy of intravenous (IV) tramadol (AVE-901) compared to placebo in the management of postoperative pain fo...

Active, not recruiting

Pain Management

Drug: Morphine

Other: Placebo